Drug Combination Details

General Information of the Combination (ID: C77873)
Name Flavopiridol   NP Info  + Rev-caspase-3   Drug Info 
Structure +
Disease
Ovarian cancer [ICD-11: 2C73]
Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [1]
                    In-vitro Model OVCAR-3 CVCL_0465 Ovarian serous adenocarcinoma Homo sapiens
                    In-vivo Model 1*107 OVCAR3 cells in 0.2 ml PBS were inoculated subcutaneously into the dorsal flank of female mice (4 to 6 weeks old and weighing 16 to 20 g).
                    Experimental
                    Result(s)		 The sequential combination of rev-caspase-3 and flavopiridol result in significant synergistic cell killing effects, significant tumor growth suppression and extended survival of mice bearing OVCAR3 cells.
References
Reference 1 Sequential combination therapy with flavopiridol and autocatalytic caspase-3 driven by amplified hTERT promoter synergistically suppresses human ovarian carcinoma growth in vitro and in mice. J Ovarian Res. 2014 Dec 21;7:121.
 Download Picture         KEGG Link